NCT03190174 2025-02-17Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain CancersSarcoma Oncology Research Center, LLCPhase 1/2 Completed34 enrolled 14 charts
NCT03715946 2025-01-13Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx CancerUniversity of PittsburghPhase 2 Completed40 enrolled 69 charts
NCT03215810 2023-07-24Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung CancerH. Lee Moffitt Cancer Center and Research InstitutePhase 1 Completed20 enrolled 10 charts
NCT03841110 2023-05-01FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsFate TherapeuticsPhase 1 Completed37 enrolled
NCT03758781 2023-04-14IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid TumorsH. Lee Moffitt Cancer Center and Research InstitutePhase 1 Completed12 enrolled